Suppr超能文献

卵巢印戒间质细胞瘤中Wnt/β-连环蛋白信号通路的致癌激活

Oncogenic Activation of the Wnt/β-Catenin Signaling Pathway in Signet Ring Stromal Cell Tumor of the Ovary.

作者信息

Kopczynski Janusz, Kowalik Artur, Chłopek Małgorzata, Wang Zeng-Feng, Góźdź Stanisław, Lasota Jerzy, Miettinen Markku

机构信息

Departments of *Surgical Pathology †Molecular Diagnostic §Chemotherapy, Holycross Cancer Centre ∥Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland ‡Laboratory of Pathology, National Cancer Institute, Bethesda, MD.

出版信息

Appl Immunohistochem Mol Morphol. 2016 May-Jun;24(5):e28-33. doi: 10.1097/PAI.0000000000000271.

Abstract

Signet ring stromal cell tumor (SRSCT) of the ovary is a very rare benign ovarian neoplasm. To date, no underlying genetic mechanism has been identified. In this study, 50 oncogenes and tumor suppressor genes were evaluated for mutations in a typical SRSCT using the next-generation DNA sequencing approach. An in-frame deletion of 30 nucleotides in the glycogen serine kinase-3 beta phosphorylation region of the β-catenin gene (CTNNB1) was identified, and the finding was confirmed by Sanger sequencing. This deletion (c.68_97del) at the protein level would lead to a p.Ser23_Ser33delinsThr oncogenic-type mutation. Subsequent immunohistochemistry showed prominent nuclear accumulation of β-catenin and cyclin D1 in tumor cells. Thus, mutational activation of the Wnt/β-catenin pathway could be a crucial event in the molecular pathogenesis of SRSCT of the ovary. These findings may also assist in the diagnosis of this rare tumor.

摘要

卵巢印戒样基质细胞瘤(SRSCT)是一种非常罕见的卵巢良性肿瘤。迄今为止,尚未确定其潜在的遗传机制。在本研究中,使用下一代DNA测序方法对一个典型的SRSCT中的50个癌基因和肿瘤抑制基因进行了突变评估。在β-连环蛋白基因(CTNNB1)的糖原丝氨酸激酶-3β磷酸化区域发现了一个30个核苷酸的框内缺失,该发现通过桑格测序得到证实。这种在蛋白质水平的缺失(c.68_97del)会导致p.Ser23_Ser33delinsThr致癌型突变。随后的免疫组织化学显示肿瘤细胞中β-连环蛋白和细胞周期蛋白D1在细胞核中显著积聚。因此,Wnt/β-连环蛋白通路的突变激活可能是卵巢SRSCT分子发病机制中的一个关键事件。这些发现也可能有助于这种罕见肿瘤的诊断。

相似文献

1
Oncogenic Activation of the Wnt/β-Catenin Signaling Pathway in Signet Ring Stromal Cell Tumor of the Ovary.
Appl Immunohistochem Mol Morphol. 2016 May-Jun;24(5):e28-33. doi: 10.1097/PAI.0000000000000271.
3
Ovarian Signet-ring Stromal Tumor: A Morphologic, Immunohistochemical, and Molecular Study of 7 Cases With Discussion of the Differential Diagnosis.
Am J Surg Pathol. 2022 Dec 1;46(12):1599-1610. doi: 10.1097/PAS.0000000000001954. Epub 2022 Aug 29.
5
MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.
Oncogene. 2011 Oct 6;30(40):4152-62. doi: 10.1038/onc.2011.123. Epub 2011 Apr 18.
6
Wnt signaling pathway analysis in renal cell carcinoma in young patients.
Mod Pathol. 2007 Dec;20(12):1217-29. doi: 10.1038/modpathol.3800957. Epub 2007 Sep 14.
7
Signet ring stromal cell tumor revisited and related signet ring cell lesions of the ovary.
Hum Pathol. 2014 Mar;45(3):636-42. doi: 10.1016/j.humpath.2013.09.012. Epub 2013 Oct 3.
8
WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.
Mol Cancer Res. 2012 Mar;10(3):469-82. doi: 10.1158/1541-7786.MCR-11-0177. Epub 2012 Jan 9.
10
Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas.
Mod Pathol. 2010 Feb;23(2):225-34. doi: 10.1038/modpathol.2009.162. Epub 2009 Nov 6.

引用本文的文献

3
An 8‑gene signature predicts the prognosis of cervical cancer following radiotherapy.
Mol Med Rep. 2019 Oct;20(4):2990-3002. doi: 10.3892/mmr.2019.10535. Epub 2019 Jul 29.
5
SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):40-45. doi: 10.1097/PAI.0000000000000500.
8
SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.
Arch Pathol Lab Med. 2017 Apr;141(4):564-568. doi: 10.5858/arpa.2016-0147-OA. Epub 2017 Feb 28.

本文引用的文献

1
Perspectives on signet ring stromal cell tumor and related signet ring cell lesions of the gonads.
Adv Anat Pathol. 2014 Nov;21(6):443-9. doi: 10.1097/PAP.0000000000000042.
2
The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
Clin Endocrinol (Oxf). 2014 Jun;80(6):899-904. doi: 10.1111/cen.12386. Epub 2014 Jan 16.
3
Frequent mutation and nuclear localization of β-catenin in sertoli cell tumors of the testis.
Am J Surg Pathol. 2014 Jan;38(1):66-71. doi: 10.1097/PAS.0b013e31829cdbc6.
4
The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.
Mod Pathol. 2014 Feb;27(2):231-7. doi: 10.1038/modpathol.2013.142. Epub 2013 Jul 26.
5
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
Mod Pathol. 2014 Jan;27(1):128-34. doi: 10.1038/modpathol.2013.107. Epub 2013 Jun 14.
6
β-catenin (CTNNB1) S33C mutation in ovarian microcystic stromal tumors.
Am J Surg Pathol. 2011 Oct;35(10):1429-40. doi: 10.1097/PAS.0b013e31822d6c71.
7
JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications.
Urol Oncol. 2013 Aug;31(6):930-7. doi: 10.1016/j.urolonc.2011.07.001. Epub 2011 Aug 24.
8
Steroid receptor coactivator (SRC) family: masters of systems biology.
J Biol Chem. 2010 Dec 10;285(50):38743-50. doi: 10.1074/jbc.R110.193367. Epub 2010 Oct 18.
9
Bilateral and multinodular signet-ring stromal tumor of the ovary.
Obstet Gynecol. 2010 Aug;116 Suppl 2:556-558. doi: 10.1097/AOG.0b013e3181e9b410.
10
Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease.
Mol Endocrinol. 2010 Jul;24(7):1322-37. doi: 10.1210/me.2009-0519. Epub 2010 Mar 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验